TIAA CREF Investment Management LLC lifted its position in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 54.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 222,351 shares of the biopharmaceutical company’s stock after buying an additional 78,133 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.48% of Acorda Therapeutics worth $4,380,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of ACOR. Dimensional Fund Advisors LP lifted its stake in shares of Acorda Therapeutics by 21.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,831,450 shares of the biopharmaceutical company’s stock worth $38,474,000 after buying an additional 323,888 shares during the last quarter. Spark Investment Management LLC lifted its stake in shares of Acorda Therapeutics by 125.1% in the second quarter. Spark Investment Management LLC now owns 433,700 shares of the biopharmaceutical company’s stock worth $8,543,000 after buying an additional 241,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Acorda Therapeutics by 6.0% in the first quarter. Vanguard Group Inc. now owns 4,139,589 shares of the biopharmaceutical company’s stock worth $86,931,000 after buying an additional 233,575 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Acorda Therapeutics by 161.7% in the first quarter. Alliancebernstein L.P. now owns 156,290 shares of the biopharmaceutical company’s stock worth $3,282,000 after buying an additional 96,560 shares during the last quarter. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Acorda Therapeutics in the second quarter worth $1,272,000.

Acorda Therapeutics, Inc. (ACOR) opened at 26.70 on Friday. The company’s 50-day moving average is $24.20 and its 200 day moving average is $19.91. The firm’s market capitalization is $1.25 billion. Acorda Therapeutics, Inc. has a 1-year low of $13.60 and a 1-year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.16. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The business had revenue of $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. During the same quarter last year, the firm posted $0.07 EPS. The company’s quarterly revenue was up 9.3% on a year-over-year basis. On average, equities analysts expect that Acorda Therapeutics, Inc. will post $1.75 EPS for the current fiscal year.

A number of analysts have recently weighed in on ACOR shares. BidaskClub upgraded shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 7th. Stifel Nicolaus restated a “buy” rating on shares of Acorda Therapeutics in a research note on Friday, July 28th. ValuEngine upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Janney Montgomery Scott restated a “hold” rating and issued a $18.00 price objective on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Finally, Zacks Investment Research upgraded shares of Acorda Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Acorda Therapeutics presently has an average rating of “Hold” and a consensus price target of $24.06.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Has $4.38 Million Stake in Acorda Therapeutics, Inc. (ACOR)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-has-4-38-million-stake-in-acorda-therapeutics-inc-acor/1642593.html.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the business’s stock in a transaction on Tuesday, August 29th. The stock was acquired at an average price of $19.23 per share, with a total value of $14,734,045.23. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Barry E. Greene sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $21.57, for a total value of $215,700.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $215,700. The disclosure for this sale can be found here. Insiders have sold a total of 20,250 shares of company stock valued at $438,650 in the last ninety days. Insiders own 7.90% of the company’s stock.

Acorda Therapeutics Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.